0001564590-21-053039.txt : 20211101 0001564590-21-053039.hdr.sgml : 20211101 20211101070522 ACCESSION NUMBER: 0001564590-21-053039 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20211101 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211101 DATE AS OF CHANGE: 20211101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 211365285 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 8-K 1 eypt-8k_20211101.htm 8-K eypt-8k_20211101.htm
false 0001314102 0001314102 2021-11-01 2021-11-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 1, 2021

 

EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

 

000-51122

 

26-2774444

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

480 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of

each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001

 

EYPT

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 1, 2021 (the “COO Start Date”), EyePoint Pharmaceuticals, Inc. (the “Company”) announced that the Board of Directors (the “Board”) of the Company appointed Jay S. Duker, M.D., age 63, as the Company's Chief Operating Officer. Dr. Duker has served as the Company’s Chief Strategic Scientific Officer in a part time capacity since July 20, 2020 and previously served as an independent member of the Company’s Board of Directors from 2016 to 2020.

 

In connection with Dr. Duker's appointment, the Company entered into an employment agreement (the “Employment Agreement”) with Dr. Duker, which provides that his employment will continue until either the Company or Dr. Duker provides notice of termination in accordance with the terms of the Employment Agreement. In addition, the Company entered into a confidential information, non-disclosure, non-solicitation, non-compete, and rights to intellectual property agreement with Dr. Duker, which prohibits him from competing with the Company, soliciting the Company's employees and customers and disclosing confidential information during the term of his employment and for a specified time thereafter.

 

Pursuant to the Employment Agreement, Dr. Duker is entitled to receive an annual base salary of $500,000. In connection with his appointment as Chief Operating Officer, the Company granted Dr. Duker options to purchase 305,000 shares of the Company's common stock at an exercise price of $11.47 per share, with 25% vesting on the first anniversary of the COO Start Date followed by ratable monthly vesting through the fourth anniversary of the COO Start Date (the “Options”). In addition, the Company granted Dr. Duker an award of 15,258 restricted stock units having a value of $175,000 as determined by the market closing price for the Company’s common stock on the business day immediately preceding the COO Start Date, with full vesting of the RSUs to occur on the first anniversary of the COO Start Date (the “RSUs”, and together with the Options, the “Equity Awards”),  The Equity Awards were made pursuant to Company's 2016 Long Term Equity Incentive Plan, as amended. In connection with his appointment as Chief Operating Officer, Dr. Duker also received a one-time cash award of $175,000, which is subject to certain repayment terms if, within one year of the COO Start Date, Dr. Duker terminates employment with the Company without “Good Cause” or the Company terminates Dr. Duker’s employment for “Cause” (as such terms are defined in the Employment Agreement). In addition, as Chief Operating Officer, Dr. Duker is eligible to receive an annual cash bonus, which is based on the achievement of individual and corporate performance objectives, calculated as a percentage of his annual base salary, and which will be determined by the Company's Board, in its sole discretion. Dr. Duker's target annual bonus is 50% of his annual base salary. In connection with his appointment, Dr. Duker has also entered into the Company's standard indemnification agreement, the form of which is filed as Exhibit 10.19 to the Company's Annual Report on Form 10-K for the year ended December 31, 2020.

 

Under the Employment Agreement, if Dr. Duker's employment is terminated by the Company without Cause or by Dr. Duker for Good Cause, Dr. Duker will be entitled to (a) his base salary for the period of 12 months from the date of termination; (b) 100% of his target bonus, payable in equal installments during the period of base salary continuation payable in clause (a); and (c) reimbursements equal to the portion of the monthly health premiums paid by the Company on Dr. Duker's behalf and that of his eligible dependents immediately preceding the date that Dr. Duker's employment terminates until the earlier of (i) the last day of the period of base salary continuation under clause (a) and (ii) that date that Dr. Duker and his eligible dependents become ineligible for COBRA coverage. In the event Dr. Duker’s employment is terminated by the Company without Cause or by Dr. Duker for Good Cause within 30 days prior to, or within 18 months following a "Change of Control" (as such term is defined in the Employment Agreement), Dr. Duker’s base salary continuation under clause (a) shall be 18 months from the date of termination, and any options to purchase shares of the Company's common stock or shares of restricted stock of the Company held by Dr. Duker that are not fully vested at the time of such employment termination following the Change of Control will immediately accelerate and vest in full.

 

In addition to the payments set forth in the preceding paragraph, upon the termination of Dr. Duker's employment for any reason, Dr. Duker will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of his termination of employment. The payments and benefits set forth above are subject to Dr. Duker's execution of a release of claims.

 

Dr. Duker brings extensive experience to the Company, having served in wide-ranging roles in clinical, research, business,

 


 

start-ups, and academic settings. In addition to his earlier roles at EyePoint, Dr. Duker was the Director of the New England Eye Center and Chair of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine, positions which he has relinquished to join the Company in a full-time capacity. Additionally, Dr. Duker co-founded three start-ups, including Hemera Biosciences, a gene therapy company that developed an anti-complement treatment for dry macular degeneration, which was acquired by Janssen in 2020. Dr. Duker is currently the Chair of the Board of Sesen Bio, a publicly traded clinical stage biopharmaceutical company. He has published more than 300 journal articles related to ophthalmology and is co-author of Yanoff and Duker’s Ophthalmology, an ophthalmic textbook. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.

 

There are no family relationships between Dr. Duker and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

The description of the Employment Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this current report on Form 8-K.

 

On the COO Start Date, the Company issued a press release announcing the appointment of Dr. Duker. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

  

Description

 

 

10.1

  

Employment Agreement, effective November 1, 2021, between EyePoint Pharmaceuticals, Inc. and Jay S. Duker, M.D.

99.1

  

Press Release of EyePoint Pharmaceuticals, Inc., dated November 1, 2021.

104

 

Cover Page Interactive Data File (embedded within the inline XBRL document).

 

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EyePoint Pharmaceuticals, Inc.

 

 

Date: November 1, 2021

 

By:

 

/s/ George O. Elston

 

 

Name:

 

George O. Elston

 

 

Title

 

Chief Financial Officer and Head of Corporate Development

 

 

EX-10.1 2 eypt-ex101_27.htm EX-10.1 eypt-ex101_27.htm

 

Exhibit 10.1

 

 

 

EMPLOYMENT AGREEMENT

 

This Amended and Restated Employment Agreement (hereinafter the “Agreement”) is made as of November 1, 2021, by and between Jay S. Duker, M.D., who currently resides at XXX (“Employee”) and EyePoint Pharmaceuticals, Inc. (formerly pSivida, Inc. and hereinafter together with its parent, subsidiary, and related or affiliated entities referred to as the “Company”), having its headquarters at 480 Pleasant Street, Suite A210, Watertown, Massachusetts 02472 (collectively the “Parties”).

 

Recitals

 

WHEREAS, the Parties previously entered into an employment agreement dated as of July 20, 2020 (the “2020 Agreement”);

 

WHEREAS, the Parties now wish to amend and restate the 2020 Agreement in its entirety to reflect the engagement of the Employee in the new role of Chief Operating Officer of the Company;

 

WHEREAS, the Employee desires to remain employed by and the Company desires to promote the Employee to be its Chief Operating Officer; and

 

WHEREAS, the Company and Employee desire to set forth the terms and conditions under which the Company agrees to employ Employee and Employee agrees to be employed by the Company as its Chief Operating Officer;

 

Agreement

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and the Employee hereby agree as follows:

 

1.Position and Duties.

 

(a)Employee will continue to be employed pursuant to the 2020 Agreement until November 1, 2021 or such other date as the Company and Employee may agree (the "COO Start Date").  As of the COO Start Date, Employee will commence employment by the Company on a full time basis as its Chief Operating Officer, reporting to the President and Chief Executive

 


 

 

Officer (“CEO”) of the Company. This is an exempt position. During Employee’s employment, Employee may be asked from time to time, to serve as a director or officer of one or more of the Company's subsidiaries, in each case, without further compensation. If Employee’s employment with the Company terminates for any reason, then concurrently with such termination, Employee will be deemed to have resigned from any director, officer, trustee, or other positions Employee may hold with the Company, the Company's subsidiaries, or any of their respective related committees, trusts, or other similar entities, in each case unless otherwise agreed in writing by the Company and Employee.

 

(b)Employee agrees to perform the duties of Employee’s position and such other duties as may reasonably be assigned to Employee consistent therewith from time to time. Employee also agrees that, while employed by the Company, Employee will devote Employee’s full business time and best efforts, business judgment, skill and knowledge to the advancement of the business interests of the Company and to the discharge of all assigned duties and responsibilities for them. Notwithstanding the preceding sentence, the Company acknowledges and agrees that, for the duration of the Term, Employee shall be permitted to continue to provide medical care and related services to Employee’s patients for a period of time not to exceed, on average, one (1) day per week (the “Physician Services”). Employee shall not be entitled to any additional compensation by the Company for the Physician Services, and the Company acknowledges and agrees that Employee shall be entitled to compensation from third parties for Employee’s provision of Physician Services.

 

(c)Employee agrees that, while employed by the Company, Employee will comply with all Company policies, practices and procedures and all codes of ethics or business conduct applicable to Employee’s position, as in effect from time to time.

 

2.Compensation and Benefits. During Employee’s employment, as compensation for all services performed by Employee for the Company and its subsidiaries and subject to Employee’s full performance of Employee’s obligations hereunder, the Company will provide Employee the following pay and benefits:

 

(a)Base Salary. The Company will pay Employee a base salary at the rate of $500,000 per year, payable in accordance with the regular payroll practices of the Company (as may be increased, from time to time, the "Base Salary").

 

(b)Bonus Compensation. For each fiscal year completed during Employee’s employment under this Agreement, Employee will be eligible for an annual cash bonus. Employee’s target bonus will be 50% of the Base Salary (the "Target Bonus"), with the actual amount of any such bonus being determined by the Board of Directors of the Company (the "Board") in its sole discretion, based on Employee’s performance and that of the Company against goals established by the Board (and for the goals based on Employee’s performance, agreed to by Employee) and consistent with any applicable plan or program documents and generally applicable Company policies. Employee’s bonus eligibility for calendar year 2021 will be subject to proration, using the terms of the 2020 Agreement to determine bonus eligibility from January 1, 2021 until the day prior to the COO Start Date, and with bonus eligibility for the remainder of calendar year 2021 subject to the Target Bonus and other terms described in this paragraph. Except

 

2


 

 

as otherwise expressly provided in Section 4 hereof, Employee must be employed through the end of the fiscal year to which a bonus relates in order to earn the bonus. Subject to Section 4 of this Agreement, if Employee’s employment terminates, for any reason, prior to the end of the fiscal year to which a bonus relates, the bonus is not earned.

 

(c)COO Equity Grants; Cash Award. With effect from the COO Start Date, Employee will be granted (A) a new award of 305,000 options (“Options”) to purchase common stock (“Stock”) with time-based vesting (i) one-quarter on the first anniversary of the COO Start Date and (ii) in equal monthly installments thereafter until vested in full on the fourth anniversary of the Start Date; and (B) an award of a number of restricted stock units (“RSUs”) having a value of $175,000 as determined by the market closing price for the Stock on the business day immediately preceding the COO Start Date.  The forms of agreement for your COO equity grants is attached hereto as Exhibit 2(c), it being understood and agreed that, notwithstanding the wording of Section 2(b)(I)(i) of the hard-coded Executive Officer Award template shown in Exhibit 2(c), the words “three-month period” shown therein shall be replaced by the words “twelve-month period” in connection with this initial equity grant.  Further, COO shall receive a one-time, lump-sum cash award of $175,000 payable on the Company’s regular payroll date immediately following the COO Start Date (the “COO Sign-On Bonus”).  The COO Sign-On Bonus shall be subject to all applicable taxes and withholdings.  Further, in the event that, on or prior to the one (1) year anniversary of the COO Start Date, Employee terminates Employee’s employment with the Company without Good Cause, or the Company terminates Employee’s employment for Cause, the COO Sign-On Bonus (net of taxes and withholdings) shall be repaid to the Company in full within ten (10) business days of such employment termination.

 

(d)Equity and Other Long-Term Incentive Grants. Commencing with the next annual award of equity or other long-term incentives to senior executives following your Start Date, you will be eligible for grants of equity and other long-term awards as approved by the Compensation Committee of the Board of Directors based on prevailing market practices and commensurate with your position relative to grants to other senior executives of the Company.

 

(e)Participation in Employee Benefit Plans. Employee will be entitled to participate in all employee benefit plans from time to time in effect for senior employees of the Company generally, except to the extent such plans are duplicative of benefits otherwise provided to Employee under this Agreement (e.g., a severance pay plan).  Employee’s participation will be subject to the terms of the applicable plan documents and generally applicable Company polices, as the same may be in effect from time to time, and any other restrictions or limitations imposed by law.

 

(f)Vacations. Employee will be entitled to four (4) weeks of vacation per year, in addition to holidays observed by the Company.  Vacation will accrue monthly on a pro-rated basis. Vacation may be taken at such times and intervals as Employee shall determine, subject to the business needs of the Company. Vacation shall otherwise be subject to the policies of the Company, as in effect from time to time.

 

(g)Business Expenses. The Company will pay or reimburse Employee for all reasonable business expenses incurred or paid by Employee in the performance of Employee’s

 

3


 

 

duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set by the Company and made known to Employee in writing, and to such reasonable substantiation and documentation as may be specified from time to time. Employee’s right to payment or reimbursement for business expenses hereunder shall be subject to the following additional rules: (i) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement shall be made not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred, and (iii) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.

 

(h)Professional Fees. The Company will pay Employee’s reasonable and documented professional fees incurred by him related to the negotiation and preparation of this Agreement and related agreements and other documents in an aggregate amount not to exceed $10,000.

 

3.Termination of Employment. Employee’s employment under this Agreement shall continue until terminated pursuant to this Section 3.

 

(a)By the Company for Cause. The Company may terminate Employee’s employment for Cause upon notice to Employee setting forth in reasonable detail the nature of the Cause. The following as determined by the Board in its reasonable, good faith judgment, shall constitute "Cause" for termination: (i) material or willful failure to perform duties reasonably expected and/or requested of Employee (other than by reason of disability) if not cured within 30 days of written notice of such failure; (ii) material breach of this Agreement or any other agreement between Employee and the Company, including but not limited to the Confidential Information, Non-Disclosure, Non-Solicitation, Non-Compete and Rights to Intellectual Property Agreement if not cured within 30 days of receipt of written notice of such breach; (iii) commission of, or plea of nolo contendere to, a felony or other crime involving moral turpitude; (iv) commission of fraudulent or other illegal act in commission of Employee’s duties or otherwise with respect to the Company; (v) failure to adhere to moral and ethical business principles consistent with the Company’s Code of Business Conduct and/or policies in effect from time to time; or (vi) engaging in an act or series of acts constituting misconduct resulting in a misstatement of the Company's  financial statements due to material non-compliance with any financial reporting requirement within the meaning of Section 304 of the Sarbanes-Oxley Act of 2002; or (vii) other conduct that is or could reasonably be expected to be harmful to the interests or reputation of the Company.

 

(b)By the Company Without Cause. The Company may terminate Employee’s employment at any time other than for Cause upon thirty (30) days’ notice to Employee.

 

(c)By Employee for Good Cause. Employee may terminate Employee’s employment for Good Cause by (A) providing notice of such termination to the Company specifying in reasonable detail the condition giving rise to the Good Cause no later than the thirtieth (30th) day following Employee’s first becoming aware of such event or condition; and (B) providing the Company a period of (30) days to remedy the event or condition; and (C) written notice terminating Employee’s employment for Good Cause within fifteen (15) days following the expiration of the period to remedy if the Company fails to remedy the condition. The following, if occurring without

 

4


 

 

Employee’s express prior written consent, shall constitute "Good Cause" for termination by Employee: (i) a material diminution in the nature or scope of Employee’s position, duties, or authority (other than temporarily while Employee is physically or mentally incapacitated to such a degree that Employee would be eligible for disability benefits under the Company's disability income plan or as required by applicable law); (ii) a material reduction in the Base Salary or the Target Bonus percentage; (iii) a material breach by the Company of this Agreement, including the failure of the Company to grant the equity benefits described in Section 2(c) above; or (iv) a requirement by the Company that Employee relocate to a location more than thirty (30) miles from Watertown, Massachusetts.

(d)By Employee Without Good Cause. Employee may terminate Employee’s employment at any time without Good Cause upon thirty (30) days' notice to the Company. The Board may elect to waive such notice period or any portion thereof; but in that event, the Company shall pay Employee the Base Salary for that portion of the notice period so waived.

 

(e)Death and Disability. Employee’s employment hereunder shall automatically terminate in the event of Employee’s death during employment. In the event Employee becomes disabled during employment and, as a result, is unable to continue to perform substantially all of Employee’s duties and responsibilities under this Agreement, either with or without reasonable accommodation, the Company will continue to pay Employee the Base Salary and to provide Employee benefits in accordance with Section 2(c) above, to the extent permitted by plan terms, for up to twelve (12) weeks of disability during any period of three hundred sixty-five (365) consecutive calendar days.

 

4.Other Matters Related to Termination.

 

(a)Final Compensation. In the event of termination of Employee’s employment with the Company, howsoever occurring, the Company shall pay Employee (i) the Base Salary for the final payroll period of Employee’s employment, pro-rated through the date that Employee’s employment terminates; (ii) compensation at the rate of the Base Salary for any accrued, unused vacation time; and (iii) reimbursement, in accordance with Section 2(e) hereof, for business expenses incurred by Employee but not yet paid to Employee as of the date Employee’s employment terminates; provided Employee submits all expenses and supporting documentation required within sixty (60) days of the date Employee’s employment terminates, and provided further that such expenses are reimbursable under Company policies as then in effect (all of the foregoing, "Final Compensation"). Except as otherwise provided in Section 5(a)(iii), Final Compensation will be paid to Employee within thirty (30) days following the date of termination (or such shorter period required by law).

 

(b)Severance Payments. In the event of any termination of Employee’s employment pursuant to Section 3(b) or Section 3(c) above, the Company will pay Employee, in addition to Final Compensation, (i) the Base Salary for the period of twelve (12) months from the date of termination, provided, however, that if such termination occurs within the thirty (30) days prior to, or within eighteen (18) months following, a Change of Control (a “CIC Termination”) the Company will instead pay you, in addition to Final Compensation, the Base Salary for the period of eighteen (18) months from the date of such CIC Termination; (ii) one times the Target Bonus,

 

5


 

 

payable in equal installments during the period of Base Salary continuation under clause (i); and (iii) provided you timely elect continuation coverage for yourself and your eligible dependents under the federal law known as “COBRA” or similar state law, a monthly amount that equals the portion of the monthly health premiums paid by the Company on your behalf and that of your eligible dependents immediately preceding the date that your employment terminates until the earlier of (A) the last day of the period of Base Salary continuation under clause (i) and (B) the date that you and your eligible dependents become ineligible for COBRA coverage pursuant to applicable law or plan terms.  The severance payments described in clauses (i) through (iii) above are referred to as the "Severance Payments". In the event a Change of Control occurs following the COO Start Date, and any options to purchase Stock or shares of restricted Stock held by Employee are assumed or substituted in such Change of Control, all such assumed or substituted options and restricted shares that remain outstanding and are not fully vested at the time of any subsequent termination of your employment pursuant to Section 3(b) or Section 3(c) shall immediately accelerate and vest in full upon such termination and the options will remain exercisable until the earlier of the first anniversary of the date of your employment termination (or three (3) months following the date of your employment termination in the case of any incentive stock options) and the last day of the option term (the “Equity Acceleration”).

(c)Conditions to and Timing of Severance Payments. Any obligation of the Company to provide Employee the Severance Payments and the Equity Acceleration is conditioned, however, on Employee’s cooperation in the transition of Employee’s duties and Employee’s execution and return to the Company of a Separation Agreement and General Release, which will include a release by Employee of all releasable claims relating to employment or separation from employment, reaffirmation of Employee’s obligations under the Confidential Information, Non-Disclosure, Non-Solicitation, Non-Compete and Rights to Intellectual Property Agreement, a twelve-month post-employment non-competition provision, and confidentiality, non-disparagement and cooperation obligations of the parties (the “Separation Agreement”) in a form substantially similar to the form attached hereto as Exhibit 4(c).  The Separation Agreement must become binding and enforceable within 60 calendar days after Employee’s termination of employment. Except as otherwise provided by this Agreement, or as may be mutually agreed by the parties, any Severance Payments to which Employee is entitled will be provided in the form of salary continuation, payable in accordance with the normal payroll practices of the Company. Unless otherwise provided by this Agreement, the first payment will be made on the Company's next regular payday following the effective date of the Severance Agreement and General Release; but that first payment shall include all amounts accrued retroactive to the day following the date Employee’s employment terminated.

 

(d)Benefits Termination. Except as provided in Section 4(b) above or under COBRA, Employee’s participation in all employee benefit plans, if applicable, shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of Employee’s employment, without regard to any continuation of the Base Salary or other payment to Employee following termination and Employee shall not be eligible to earn vacation or other paid time off following the termination of Employee’s employment.

 

(e)Assistance in Litigation. Employee agrees to reasonably cooperate with the Company in the defense or prosecution of any claims or actions that relate to events or occurrences

 

6


 

 

that transpired while Employee is or was employed by the Company. Employee’s cooperation includes, but is not limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company as requested at mutually convenient times. Employee’s cooperation also includes fully cooperating with the Company in connection with any investigation or review by any federal, state, or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while Employee is or was employed by the Company. The Company shall pay Employee all expenses relating to such cooperation, and shall pay for his time at his then current consulting rate for all such cooperation (other than the execution and return of documents) during any period that the Company is not paying Employee wages or post-employment separation pay.

 

(f)Survival. Provisions of this Agreement shall survive any termination of employment if so provided in this Agreement or if necessary or desirable to accomplish the purposes of other surviving provisions, including without limitation each party’s obligations under Section 4. The obligation of the Company to make payments to Employee under Section 4(b), are expressly conditioned upon continued full performance of Employee’s obligations under Section 4 hereof. Upon termination by either Employer or the Company, all rights, duties and obligations of Employee and the Company to each other shall cease, except as otherwise expressly provided in this Agreement.

 

5.Timing of Payments and Section 409A.

 

(a)Notwithstanding anything to the contrary in this Agreement, if at the time Employee’s employment terminates, Employee is a "specified employee," as defined below, any and all amounts payable under this Agreement on account of such separation from service that would (but for this provision) be payable within six (6) months following the date of termination, shall instead be paid on the next business day following the expiration of such six (6) month period or, if earlier, upon Employee’s death; except (A) to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation Section l.409A-1(b) (including without limitation  by reason  of  a short-term  deferral  or the safe  harbor  set  forth  in Section  l.409A­ l (b)(9)(iii), as determined by the Company in its reasonable good faith discretion); (B) benefits which qualify as excepted welfare benefits pursuant to Treasury regulation Section l.409A­ l(a)(5); or (C) other amounts or benefits that are not subject to the requirements of, or satisfy an exception from treatment as deferred compensation under, Section 409A of the Internal Revenue Code of 1986, as amended ("Section 409A"). For purposes of this Agreement, all references to "termination of employment" and correlative phrases shall be construed to require a "separation from service" (as defined in Section l.409A-l(h) of the Treasury regulations after giving effect to the presumptions contained therein), and the term "specified employee" means an individual determined by the Company to be a specified employee under Treasury regulation Section l.409A-l(i).

 

(b)Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.

 

 

7


 

 

 

(c)In no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A.

 

6.Definitions. For purposes of this Agreement, the following definitions apply: "Change of Control" means

(a)The acquisition by any Person (defined for purposes of this definition as any individual, entity or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended ("Exchange Act")) of  beneficial  ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 35% or more of the common stock of the Company; provided, however, that for purposes of this subsection (A), an acquisition shall not constitute a Change of Control if it is: (i) either by or directly from the Company, or by an entity controlled by the Company, (ii) by any employee benefit plan, including any related trust, sponsored or maintained by the Company or an entity controlled by the Company ("Benefit Plan"), or (iii) by an entity pursuant to a transaction that complies with clauses (i), (ii) and (iii) of subsection (b) below; or Individuals who, as of the effective date of this Agreement, constitute the Board (together with the individuals  identified  in the proviso to  this subsection  (B), the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the effective date of this agreement whose election, or nomination for election by the Company's stockholders, was approved by at least a majority of the directors then comprising the Incumbent Board shall be treated as a member of the Incumbent Board unless he or she assumed office as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

 

(b)Consummation of a reorganization, merger or consolidation involving the Company, or a sale or other disposition of all or substantially all of the assets of the Company (a "Transaction"), in each case unless, following such Transaction, (i) all or substantially all of the Persons who were the beneficial owners of the common stock of the Company outstanding immediately prior to such Transaction beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding voting securities of the entity resulting from such Transaction (including, without limitation, an entity that as a result of such Transaction owns the Company or all or substantially all of the Company's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Transaction, of the outstanding common stock of the Company, (ii) no Person (excluding any entity or wholly-owned subsidiary of any entity resulting from such Transaction or any Benefit Plan of the Company or such entity or wholly-owned subsidiary of such entity resulting from such Transaction) beneficially owns, directly or indirectly, 35% or more of the combined voting power of the then outstanding voting securities of such entity except to the extent that such ownership existed prior to the transaction and (iii) at least a majority of the members of the board of directors or similar board of the entity resulting from such Transaction were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Transaction; or

 

 

8


 

 

 

(c)Approval by the stockholders of the Company of a liquidation or dissolution of the Company.

 

"Person" means an individual, a corporation, a limited liability company, an association, a partnership, an estate, a trust or any other entity or organization, other than the Company or any of its subsidiaries.

 

7.Conflicting Agreements. Employee hereby represents and warrants that the signing of this Agreement and the performance of Employee’s obligations under it will not breach or be in conflict with any other agreement to which Employee is a party or is bound, and that Employee is not subject to any covenants against competition or similar covenants or any court order that could affect the performance of Employee’s obligations under this Agreement. Employee agrees that Employee will not disclose to or use on behalf of the Company any confidential or proprietary information of a third party without that party's consent.

 

8.Withholding. All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law.

 

9.Assignment. Neither Employee nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, the Company may assign its rights and obligations under this Agreement without Employee’s consent to one of its subsidiaries or to any Person with whom the Company shall hereafter effect a reorganization, consolidate or merge, or to whom the Company shall hereafter transfer all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon Employee and the Company, and each of its respective successors, executors, administrators, heirs and permitted assigns.

 

10.Severability. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

 

11.Miscellaneous; Cross-Consideration. This Agreement sets forth the entire agreement between Employee and the Company, and replaces all prior and contemporaneous communications, agreements and understandings, written or oral, with respect to the terms and conditions of Employee’s employment, other than (a) the Confidential Information, Non-Disclosure, Non-Solicitation, Non-Compete and Rights to Intellectual Property Agreement dated November 1, 2021, a copy of which is attached as Exhibit 11 and incorporated herein by reference, and (b) any equity grants, agreements or plans, as each may be amended from time to time, relating to Employee’s service as a director or as an employee whether or not prior to the COO Start Date. Employee acknowledges that (i) Employee’s eligibility to receive Severance Payments and other benefits pursuant to Section 4(b) of this Agreement, and (ii) Employee’s receipt of the grant of stock options set forth in Section 2(c) of this Agreement are contingent upon Employee’s agreement to the non-competition provisions set forth in the Confidential Information,

 

9


 

 

Non-Disclosure, Non-Solicitation, Non-Compete and Rights to Intellectual Property Agreement. Employee further acknowledges that such consideration was mutually agreed upon by Employee and the Company, and is fair and reasonable in exchange for Employee’s compliance with such non-competition obligations. This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by Employee and an expressly authorized representative of the Board.

 

12.Notice. Any notice required to, or permitted to, be given under this agreement shall be sufficient if in writing (a) delivered personally, (b) sent by first class certified mail, return receipt requested, postage and fees pre-paid, (c) sent by prepaid overnight delivery service, to the Parties at the following addresses (or at such other addresses as shall be specified by the Parties in a like notice); or (d) in a signed document attached to an e-mail.

 

 

If to Company:

EyePoint Pharmaceuticals, Inc.

 

 

480 Pleasant Street

 

 

Suite A-210

 

 

Watertown, MA 02472

 

 

Attention: Chief People Officer

 

 

E-mail:  jleonard@eyepointpharma.com

 

 

 

 

If to Employee:

Jay S. Duker, M.D.

 

 

XXX

 

All notices shall be deemed to have been given upon the business day of receipt.

 

13.Indemnification. During Employee’s employment, and for all periods thereafter for which he may be subject to liability for his acts or omissions to act with respect to his duties to the Company as an officer, the Company shall indemnify Employee pursuant to an Indemnification Agreement substantially in the form attached hereto as Exhibit 13.

 

14.Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts, without regard to its conflicts of law provisions. Any claim arising out of, or relating to this Agreement including, without limitation, any action commenced by the Company for preliminary and permanent injunctive relief or other equitable relief, shall be instituted in any federal or state court in the Commonwealth of Massachusetts.  Each party agrees not to assert by way of motion, as a defense or otherwise, in any such claim, that such party is not subject personally to the jurisdiction of such court, that the claim is brought in an inconvenient forum, that the venue of the claim is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.  Each party further irrevocably submits to the exclusive jurisdiction of such court in any such claim.  

 

Any and all service of process and any other notice in any such claim shall be effective against any party if given personally or by registered mail, return receipt requested, mailed to such party as provided herein. Nothing herein contained shall be deemed to affect the right of any party to serve process in any manner permitted by law.

 

10


 

 

 

15.Usage. All pronouns and any variations thereof shall be considered to refer to the masculine, feminine or neuter, singular or plural, as the context may require. All terms defined in the Agreement in their singular or plural forms have correlative meanings when used herein in their singular or plural forms, respectively. Unless otherwise expressly provided the words “include” “includes” and “including” do not limit the preceding words or terms and shall be deemed followed by the words “without limitation.”

 

16.Headings. The headings in this Agreement are for reference only, and shall not affect the interpretation of this Agreement.

 

17.Counterparts. This Agreement may be executed by the parties hereto in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts, together shall constitute one, and the same, instrument. Each counterpart may consist of a number of copies hereof each signed by less than all, but together signed by all of the parties hereto.

 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

 

 

 

 

11


 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

 

 

EyePoint Pharmaceuticals, Inc.

 

 

 

 

 

 

 

 

By:

/s/Nancy Lurker

 

 

/s/Jay Duker

 

 

Nancy Lurker

 

 

Jay S. Duker, M.D.

 

 

President & CEO

 

 

 

 

 

Date:

10/13/2021

 

 

Date:

10/13/2021

 

 

 

 

12


 

 

 

EXHIBIT 2(c)

 

Equity Grant Agreement

 

 

 

13


 

 

EXHIBIT 4(c)

 

Form of Separation and Release Agreement

 

 

 


 

 

EXHIBIT 11

 

Confidential Information, Non-Disclosure, Non-Solicitation, Non-Compete and

Rights to Intellectual Property Agreement

 

 

 


 

 

EXHIBIT 13

 

Indemnification Agreement

 

 

EX-99.1 3 eypt-ex991_6.htm EX-99.1 eypt-ex991_6.htm

 

Exhibit 99.1

 

 

EyePoint Pharmaceuticals Appoints

Jay S. Duker, M.D. as Chief Operating Officer

 

WATERTOWN, Mass., November 1, 2021 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO). Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of EyePoint’s Board of Directors since 2016. In his new full-time role as COO, Dr. Duker will be responsible for overseeing all clinical development, research, product development and manufacturing.

 

“We are very excited to have Dr. Duker join the EyePoint team in this critically important role. Jay is the right person at the right time for EyePoint. He is a proven retinal disease expert who will help drive our company’s emergence as a leader in the development of next generation ophthalmic therapeutics for serious eye diseases like wet AMD. His vast experience in the formation and execution of business strategies for innovative ophthalmological diagnostics and treatments complements and enhances the already strong capabilities of our executive team as EyePoint continues to develop and advance new products through the pipeline,” said Nancy Lurker, CEO of EyePoint Pharmaceuticals.

“In addition, Jay’s extensive clinical expertise in treating retinal diseases coupled with a successful track record as a repeat entrepreneur make him uniquely qualified for this important new role at EyePoint.  We are confident that as COO, Jay will continue to be a tremendous asset to our team as we grow our organization and expand our exciting pipeline of ocular products that have the potential to disrupt current treatment paradigms,” said Dr. Goran Ando, Chair of the Board, EyePoint Pharmaceuticals.

“It’s an honor to be taking on a greater role at EyePoint and I’m excited for the challenge of driving EyePoint’s innovative products to help patients suffering from serious eye diseases. EyePoint already has a significant foundation in place with compelling vision, great people, excellent science, and a promising pipeline, and I am particularly excited about the culture and the team at EyePoint,” said Dr. Duker. “After over 30 years in academic ophthalmology and 21 years at Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine, I look forward to the new challenges offered to me by EyePoint.”

Dr. Duker has extensive experience with wide-ranging roles in clinical, research, business, start-ups, and academic settings. In addition to his earlier roles at EyePoint, Dr. Duker was the Director of the New England Eye Center and Chair of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine, positions which he has relinquished to join EyePoint in a full-time

 


 

capacity. Dr. Duker has co-founded three start-ups, including Hemera Biosciences, a gene therapy company that developed an anti-complement treatment for dry macular degeneration, which was acquired by Janssen in 2020. In addition, Dr. Duker is currently the Chair of the Board of Sesen Bio, a publicly traded clinical stage biopharmaceutical company. He has published more than 300 journal articles related to ophthalmology and is co-author of Yanoff and Duker’s Ophthalmology, a best-selling ophthalmic textbook. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.

 

About EyePoint Pharmaceuticals, Inc. 

EyePoint Pharmaceuticals (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

 

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the anticipated use of proceeds for the proposed offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes our expectations regarding the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a novel twice-yearly treatment for serious eye diseases, including wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy and the impact of general business and economic conditions; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science;

 


 

our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

 

Investors:

 

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

 

Media Contact

 

Amy Phillips

Green Room Communications

Direct: 412-327-9499

aphillips@greenroompr.com

 

 

 

GRAPHIC 4 g3dzppm3pyvq000001.jpg GRAPHIC begin 644 g3dzppm3pyvq000001.jpg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end GRAPHIC 5 gph5ej5ysemy000001.jpg GRAPHIC begin 644 gph5ej5ysemy000001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^J6H3WR0 ME--M8YK@]#/)LC7W) )/T _*II+E5O(K53F5U+D>BC'/YD"L?Q;XHM_"VDFY MD427$A*P0Y^^WJ?8=_\ Z]$7=V1I"E.6JY[8.&/ZUYB8]2E;>\DI;U:7G^==)J^MZAKMXUUJ%R\KD_*N?E0>BCL*H* M=K!L X.<'I7;&32L?04SU2\B4?P^873\5.1^E>H> M$/C1%=RI9>)(X[=VX6\B&$)_VQ_#]1Q]*XV![2_CVM$HD Y7&#^%8.LZ'Y , MT ROI_GO0^6>DD;N?N-_SS^A[>_'>O<*Y9P<'9GBM684445 CSWQC\1KC2-H %9_P!J^+\GS_8-,CS_ 93C_QXUC^'OG_:#U)F MY*M-@GM\N/Y5[56\FH621;LC@-#N/B6=8MEUFRTU=/+_ +]XV7<%QVPW]*[^ MBO,_BE%K^DFU\3:)J-VD-LRBZM5E;R\ \,5S@CL?P]ZA>_*VPMV>F45D>&?$ M%KXGT"VU2UP!*N)(\Y,;C[RGZ?RP:S/'_BV/PCX[=VQZ+U_ M(=ZE1;?**SO8ZJBN&^&.FZS!H)U/7=1O+FYO@'CBN)6811]N">"@ZF=+TVS+!Y8R0S!3M+$CDDGH 0,52IW;5]A\NI[+17EX^%.L M]6\>:KN[D!__ (Y6YX7\$:EX?U87ESXJO]2B\MD^SS[MI)[\N>GTI.,;:,5E MW-?QGK5SX>\(ZAJMHD;SVZJ4$H)7)8+S@CUKS_1/$7Q.\3:9'J6FPZ2+60LJ ME@ <@X/!)/6NN^*/_)-]8_W(_P#T8M4_@_\ \DYLO^NLO_H9JXV5/FMU*6D; MF5-K?Q3T>(W%YH>GW\"#+BWY?'L%;/Z&NE\%^.].\96T@A1K:^A&9K9SD@>H M/<5U=>*: JVW[0>H168"PLTWF!.G*;C_ ./T*TT]+6$K-'M=%>??$KQY<>&4 MM]+TE!)J]X,H=N[RE)P#CNQ/ 'M6-9_"K6M9@6[\3>)KW[5(-QAC8MY?MDG' MX 8J5#2\G8+:79ZU17CVJ> /$WA"T?5/#'B*\N!;C?):R9RRCDX&2K?0BNT^ M'WC-/&6AM/(BQ7UNP2YC7ID]&'L>?R-$H67,G= UI='6T5XU\8KB:+Q7X=6* M:1 1R%8C/SBO4O$C,GA?5W1BK+93$,#@@[#S2<+)/N*QIT5\R^"/$FK>$[J/ M6R)IM'DF^RW2[LC. >G9@.1ZX(KZ4M+N"_LX;NUE66WF0/&ZGA@>AIU*;@QR MC8FIK.J?>8+GU.*\:^.DLD=]H(21U!68_*Q'=*[?QCX!M/&C6,ES?7%L;9&4 M"( [MV.N?I1R))-O<+'6^=%_SU3_ +Z%'G1?\]4_[Z%>-:]\&M-TCP_J&HQZ MM>.]K;O,J,JX8JI.#6)\/OAM9>,=!FU"YU&YMWCN6A"1J"" JG//^]5>SA:_ M-^ ^56O<^@!-$>DB?]]"BO+4^!FEHV1K5_T[*M%3RP_F_ 5EW-:#Q"J^/YI) M7Q;MFU!/10#P?^^A^M-EF-C[1PJ=7I_D?7TL'"G451=%8QJ***^A M.LM=I_P (-X\_Z'R7_OAO\:P=#86W[0NH),0C2/*$ M![Y3,)+RTC;,EN4/[P8Z M&[MI;:XC62&5"DB,,AE(P0:EHK%R;=R6[GB6E7,GPG\?S:7>R/\ V!J'S1RM MDA1_"WU'W6]N?2ET>WF^*OQ!EUB\C;^P=.8+%$W1L-3+%=H(WQRN0<_G@?E6Y\,[:&V^'ND^3&J>;&9'P/O,2E?.O@CQ?9>$/%6MW%[;W4ZSED46ZAB"')YR17T57BGP?POCCQ'&V MVUN#[2@_*C '05#<+:(FZ['(_%'_DF^L?[D?_HQ:\^\ M!>*O$^D^$K:VT[PE-J-FKN4N$*2K_:?[1B1W M'S);N"@/;9#N'_CW->UUXEJ\B^'/V@+>^NR$MKID8.W >/R\_0,#7MM55^S MZ#ET#J,&O$OA9_Q+_BCXATV'BW"S*%'3Y)0%_0FO:IIH[>"2:9U2*-2[NQP% M Y)->+?"-&U7Q]X@UQ%80,LF"1WDDW ?DIHI_!(([,?\9O\ D;?#GT_]J"O5 M/$W_ "*FL?\ 7C-_Z :\K^,W_(V^'/I_[4%>J>)O^14UC_KQF_\ 0#3E\,!O M9'E_PCT>SU_P)KFF7T>^">YP?53L&&'N#S3_ -K5WX&\3S>"=>D_P!&>3-E M.>%RQXQ_LM^C9'V;IO]4) M]^WH?QJI27.XRV8V]6F<3\=_^/\ T#_=F_FE>T)_JU^@KY=\3>*KGQ%I^BVN MHI(-0TWS(9G<,W_H!KC_@=_R)5W_U_O\ ^@)78>-?^1'UW_KQF_\ 0#7'_ [_ )$J[_Z_ MW_\ 0$I+^$_42^$]-HHHK$D\8UNT:QUN\MR,;925_P!T\C]"*H5Z#X[T1IHU MU6!"KJO14EOU]3"U32_+W7%NOR=7 M0?P^X]JQZ[6L'5-+\LM<6Z_)U9!_#[CVKV1V"JJC))/0"K^FZ#JNKRB.PL)YB3]Y4^4?5CP*]>\$_#N+0)%U'4F2?4 / MD5>4A^GJWO\ _KKVY343CQ6-I8>-V[OL>6_$/P))X8L-*U!69_/C$5R,Y"38 MSQ[$9'_ ?>OI0W9 M:]\-]5@\2S>(O"&J)8WDQ+2PR<*2>6P<$$$\X(ZUZ;11&3CL"=CRX0_%\%X_B NKAO$D]@VG^6V5A"[MW;H*[6BFYW5K(+F-XJT-O$GAF M]TA9Q URJ@2%=P7#!NF1Z5#X-\.-X4\-0:2]R+EHF=C($V@[F)Z9/K6_14\S MMRA?2P4444A'+^-?!%AXST](IV,%W#DP7*KDKGJ".X/I7'VVC_%;P_$+2QU" MRU&UC&V/S6!(';E@#^&37K%%6JC2MN-29Y)>>%/B1XL3[+KNK6MC8-_K(H2/ MF'T4?-]"V*]"\,>&;#PIHZ:=8*2N=TDK_>E?NQK9HHE-M6Z VV<1XV\ R>+= M8TR^34%MA9\%#%NW?,#UR,=*ZW4[/^T=*O+'?Y?VF!X=^,[=RD9Q^-6J*3DV MDNP79RG@3P9_PA6F7-I]N^UF>;S=WE;,< 8QD^E=7112;;=V)NYYSXL^$EEX MDU_^U;>_-@\N#<(L.\.P_B'(P2.OYUZ*!A0/04M%-R;23Z#;;*&MZ<=7T*_T MT2B(W5N\(D*YV[@1G'>L;P'X2?P;H*0QR(R.IP588(IM>VW>G65\,75K#-Z%T!(_&LQO!^ MA,V[[ !["1@/YUY,\IJ)^[)'MPSJFU[\7?R_I'*:)XYGLHEMK^-KB)1A9%/S M@?UKM[#4SJ2"2&TN(HC_ !SJ$S]!G)HM=#TNR8-;V,",.C;:T*]+#4: MU-6J3O\ UW/)Q5>A4E>E"W]=@HHHKK.(**** /*KB2SFG\3%7U1_$"7TR6!M M6G.TA5\L?+\@7=USQCK71ZGJEYIOBO0S/;WET[:;/YT%FN_+[HOFVY P.>?> MM+PM&(Y->P2=^K3,<_[J4MW&#X]TN3)W+87('XO%6K>MBKE+PSJ4NH>)O$3L;,'R M9^7Y%8?4UKZGNMY/',\4C)(UI%AA_"?)89%6-;TNTLO"VDFVB$;6-S9F!E ! M&'5.3WRI(/UIZ??_ )#,/7+O18O&6N-KSZB8X8K86QMFG C+*V>8SA23MQFK M.LQ:Y)X'\.6EU>SVNK3WL,3S!_G4D.5W8ZGA<^IS6S;Z=;7_ (F\56UTGFPW M4%M'*C="-CC^M95M)+?>%?"SW,SRR0ZK&@D8_,P1I%!;U. ,FB^W]= *]CM)[<@H);AHW:7_>5=J@'H,*Q&:P3=W/\ PH_[5]IF^T?9<^=YAWY\ MS^]UJ/X<>-]8\3ZS=V>HF QPP;U,<>TD[@.>?>LGSY_^$L_X0#SF_L(W&=F! MYFS=YGE[L?=SQZXXS347?4+:G7_$'3;=_#\^I;KA+N+R8T>*YD3"F50>%8#H MQYQ3_%-E%H?@FXCTYIX1]IMVW&=V;F:,'YF).,=LU>\;1";PE=HQ(!>'I_UU M2D\;Q";PK.C$@&>W/'M,E1%O3U$NA1EL8_$?C'5+34);AK/3H(!#;Q3O$I>3 M:P_B+J MMWX1U"#6M)D"7%\@M[A)%#1N$R5;'7<-Q&<]*T["5MI]>:Y_P#LRWD\0^)]/PR6U_I\32HF!ABLD9(] M"5 _*N6\ >-]9U76WTB[>%K>VMGV,(\,=F ,GI^E#C=70-&YX5M[&RU.WM-6 MAO;?Q(D9+27%W*Z7A PSQG=M8=]N 5].,UW=>2^"_$6H^-?%<"ZO(FS3=UQ" FD*!07QLRW EX-101.SCH 6 eypt-20211101.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 7 eypt-20211101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer EX-101.PRE 8 eypt-20211101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 eypt-8k_20211101_htm.xml IDEA: XBRL DOCUMENT 0001314102 2021-11-01 2021-11-01 false 0001314102 8-K 2021-11-01 EyePoint Pharmaceuticals, Inc. DE 000-51122 26-2774444 480 Pleasant Street Watertown MA 02472 (617) 926-5000 false false false false Common Stock, par value $0.001 EYPT NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 01, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 01, 2021
Entity Registrant Name EyePoint Pharmaceuticals, Inc.
Entity Central Index Key 0001314102
Trading Symbol EYPT
Entity Emerging Growth Company false
Entity File Number 000-51122
Entity Tax Identification Number 26-2774444
Entity Address, Address Line One 480 Pleasant Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 926-5000
Entity Incorporation, State or Country Code DE
Title of 12(b) Security Common Stock, par value $0.001
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *HX85,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "J.&%39.>YO^T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*$I9#R;U96.G%@8K;.QF;+4UBQ-C:R1]^R5>FS*V!]C1TN]/ MGT"-"=+TD9YC'RBRHW0W^K9+TH2-.#$'"9#,B;Q.Y93HIN:ACU[S](Q'"-I\ MZ"-!755K\,3::M8P XNP$(5JK)$FDN8^7O#6+/CP&=L,LP:H)4\=)\ 20:AY M8CB/;0,WP QCBCY]%\@NQ%S]$YL[("[),;DE-0Q#.:QR;MH!X6VW?&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MJCAA4^6C@N0^! 3! !@ !X;"]W;W)KP%-;,N590C? MOBM#;"YGUDSS$&RL_?NGE?1?B?Y:FY=L"6#9:QPEV55K:6WZV?.R8 FQS,YT M"@D^F6L32XNW9N%EJ0$9%D%QY G?O_!BJ9+6H%]\-S:#OLYMI!(8&Y;E<2S- MYAHBO;YJ\=;;%T]JL;3N"V_03^4")F!_3\<&[[Q2)50Q))G2"3,POVH-^>=K MT78!18L_%*RSO6OFNC+3^L7=W(=7+=\1002!=1(2/U8P@BAR2LCQ[TZT5;[3 M!>Y?OZG?%9W'SLQD!B,=/:O0+J]:O18+82[SR#[I]:^PZU#'Z04ZRHK_;+UM MVVZW6)!G5L>[8"2(5;+]E*^[1.P%G/,# 6(7( KN[8L*RAMIY:!O])H9UQK5 MW$71U2(:X53B1F5B#3Y5&&<'-SK(, ML!.\W@J* X*/>G7&?'["A"_X]^$>LI6 H@04A=[Y ;V17H%A?P]GF34XA/\0 MDN>EY'DAV6[J\W230ET/Z?#>Z1<"HEU"M$F5(1*$!<5=)!=U%'3\7$89$!R= MDJ-S7#+&8)1V06Q5@^DYPI@=G!&BW!.T> SK"-!H9H6H(K^P+;.I0 M:27?]_DY;W-?$%B]$JM'BDV-#%6R8)--/--1'0P=?_OG>$I@7)88E\=DYS8& MLW XOV"\7;*1CE.9U.:(UFN:^=ROO,\_ANQ.1< >\W@&IM;O:!$BVVWC'T58^3$7QQ .P]! AFMH M=\&^8COV+:E=GPV2[9[/QA'(S*UQ?(#%C$*M?)[33OT>=>3NM&%3O:ZO;+3< M,]JBL3_$?@]7^3^G#?P]W,2BO*,;&[U225"?2%KS84BA526!TT[^'FVL,XN^ M]I=*<=6&]6"THB_:77*!5#6!TV9>C.$0-Z"'46B!CQ>\^XE"J5R?TV;]56,5 MP:*B$](^:)%+7)X=]!"*J#)\WN#8;QNX0)M4F\(X]F;62.=8H3:',T>KW]Q2 MD%4YX+1_3Y5%O]5SQL7'V2ROD%;=5C ZOTH;]!K)*ML7M$7_0':?93F2-0+^S^. MWQS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1< M>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6 ME :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,H MH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+ M3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC M%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8 M\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W M5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76 M^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1G MA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ M;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^: M0ERHY_U=3_ 102P,$% @ JCAA4Y>*NQS $P( L M !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,. M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MY MEJ6R!F_236P@R*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88 M!.R '<(Y_A^[<#K3P&]'@!6^AC(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 > M"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DN MR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$% @ JCAA4R0> MFZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W M;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9 MHIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJ MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( *HX M85-ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"% MKQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/ M$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4 MZ]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N M6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC M JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@A MLO7L^T%.6X.^DYO^T K M @ $0 @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 M " "J.&%3F5R<(Q & "<)P $P @ '+ 0 >&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( *HX85/EHX+D/@0 $P0 8 M " @0P( !X;"]W;W)K&PO&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "J.&%399!YDAD! #/ P M$P @ &6$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 .."0 ) #X" #@$P ! end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports eypt-8k_20211101.htm eypt-20211101.xsd eypt-20211101_lab.xml eypt-20211101_pre.xml eypt-ex101_27.htm eypt-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "eypt-8k_20211101.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "eypt-8k_20211101.htm" ] }, "labelLink": { "local": [ "eypt-20211101_lab.xml" ] }, "presentationLink": { "local": [ "eypt-20211101_pre.xml" ] }, "schema": { "local": [ "eypt-20211101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "eypt", "nsuri": "http://eyepointpharma.com/20211101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "eypt-8k_20211101.htm", "contextRef": "C_0001314102_20211101_20211101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "eypt-8k_20211101.htm", "contextRef": "C_0001314102_20211101_20211101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001564590-21-053039-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-053039-xbrl.zip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Ǵ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end